Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment

European Urology

Volumn 58, Issue 6, 2010, Pages 831-835

  Soloway, Mark S ^a   Soloway, Cynthia T ^a   Eldefrawy, Ahmed ^a   Acosta, Kristell ^a   Kava, Bruce ^a   Manoharan, Murugesan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Active surveillance; Prostate cancer; Sexual function

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTINENCE; CONTROLLED STUDY; DISEASE SURVEILLANCE; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SEXUAL FUNCTION; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ANDROGEN ANTAGONISTS; BIOPSY; DISEASE-FREE SURVIVAL; FLORIDA; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 78049478880     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.08.027     Document Type: Article

References (25)

1. H. O'Donnell, and C. Parker What is low-risk prostate cancer and what is its natural history? World J Urol 26 2008 415 422
2. M.R. Cooperberg, J.W. Moul, and P.R. Carroll The changing face of prostate cancer J Clin Oncol 23 2005 8146 8151
3. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
4. C.J. Savage, H. Lilja, A.M. Cronin, D. Ulmert, and A.J. Vickers Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening Cancer Epidemiol Biomarkers Prev 19 2010 1201 1207
5. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101 (Pubitemid 40617061)
6. P.J. Bastian, B.H. Carter, and A. Bjartell Insignificant prostate cancer and active surveillance: from definition to clinical implications Eur Urol 55 2009 1321 1332
7. M.A. Dall'Era, M.R. Cooperberg, and J.M. Chan Active surveillance for early-stage prostate cancer: review of the current literature Cancer 112 2008 1650 1659
8. L. Klotz Active surveillance for favorable risk prostate cancer: rationale, risks, and results Urol Oncol 25 2007 505 509
9. E.Z. Neulander, R.C. Duncan, R. Tiguert, J.T. Posey, and M.S. Soloway Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision BJU Int 85 2000 699 704
10. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
11. A.M. Nieder, and M.S. Soloway It's not a radical prostatectomy, it's a total prostatectomy Eur Urol 54 2008 715 716
12. J.C. Cappelleri, and R.C. Rosen The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience Int J Impot Res 17 2005 307 319
13. K. Avery, J. Donovan, T.J. Peters, C. Shaw, M. Gotoh, and P. Abrams ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence Neurourol Urodyn 23 2004 322 330
14. S. Roemeling, M.J. Roobol, M.W. Kattan, T.H. van der Kwast, E.W. Steyerberg, and F.H. Schroder Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations Cancer 110 2007 2218 2221
15. R.M. Martin, D. Gunnell, F. Hamdy, D. Neal, A. Lane, and J. Donovan Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era J Urol 176 2006 439 449
16. G. Ploussard, E. Xylinas, and L. Salomon The role of biopsy core number in selecting prostate cancer patients for active surveillance Eur Urol 56 2009 891 898
17. R.C.N. van den Bergh, S. Roemeling, and M.J. Roobol Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 55 2009 1 8
18. A. Rajinikanth, M. Manoharan, C.T. Soloway, F.J. Civantos, and M.S. Soloway Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years Urology 72 2008 177 182
19. F.H. Schröder, M.J. Roobol, T.H. van der Kwast, R. Kranse, and C.H. Bangma Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49 2006 460 465 discussion 465
20. M.F. O'Brien, A.M. Cronin, and P.A. Fearn Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy J Clin Oncol 27 2009 3591 3597
21. A.R. Helgason, J. Adolfsson, P. Dickman, M. Fredrikson, S. Arver, and G. Steineck Waning sexual function - the most important disease-specific distress for patients with prostate cancer Br J Cancer 73 1996 1417 1421
22. M.S. Soloway, C.T. Soloway, S. Williams, R. Ayyathurai, B. Kava, and M. Manoharan Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience BJU Int 101 2008 165 169
23. K.S. Tseng, P. Landis, J.I. Epstein, B.J. Trock, and H.B. Carter Risk stratification of men choosing surveillance for low risk prostate cancer J Urol 183 2010 1779 1785
24. S.B. Zeliadt, S.D. Ramsey, and D.F. Penson Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer Cancer 106 2006 1865 1874
25. K. Fujita, P. Landis, B.K. McNeil, and C.P. Pavlovich Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance J Urol 182 2009 2664 2669